NASDAQ:ADGM Adagio Medical Q1 2026 Earnings Report $0.14 0.00 (-2.20%) Closing price 04:00 PM EasternExtended Trading$0.14 +0.00 (+2.17%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Adagio Medical EPS ResultsActual EPS-$0.31Consensus EPS -$0.29Beat/MissMissed by -$0.02One Year Ago EPSN/AAdagio Medical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAdagio Medical Announcement DetailsQuarterQ1 2026Date5/12/2026TimeBefore Market OpensConference Call DateTuesday, May 12, 2026Conference Call Time8:00AM ETUpcoming EarningsAdagio Medical's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Adagio Medical Earnings HeadlinesAdagio Medical Converts Notes to Equity Amid ReviewOctober 1, 2026 | tipranks.comAdagio Medical (NASDAQ:ADGM) & Femasys (NASDAQ:FEMY) Financial ReviewSeptember 25, 2026 | americanbankingnews.comThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tariff-driven supply chain shocks continue to build beneath market headlines. Parkview Capital's new Market Crash Survival Guide breaks down what's happening under the surface and how investors are positioning their retirement savings in response.October 6 at 1:00 AM | Parkview Capital Group (Ad)Adagio Medical Initiates Strategic Review and Workforce Reduction While Advancing vCLAS PMASeptember 23, 2026 | finance.yahoo.comAdagio Medical Announces Strategic Review Process to Maximize Shareholder ValueSeptember 23, 2026 | finance.yahoo.comAdagio Medical Explores Strategic Alternatives, Cuts WorkforceSeptember 23, 2026 | tipranks.comSee More Adagio Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adagio Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adagio Medical and other key companies, straight to your email. Email Address About Adagio MedicalAdagio Medical (NASDAQ:ADGM), Inc. is a medical-device company focused on developing catheter-based technologies for the treatment of cardiac arrhythmias, including atrial fibrillation. The company’s work is centered on cardiac ablation, a procedure that uses energy to create targeted lesions in heart tissue responsible for abnormal electrical signals. Its lead technology is the iCLAS system, an integrated cardiac liquid ablation platform designed to support cardiac ablation procedures using ultra-low-temperature cryoablation and pulsed-field ablation capabilities. The system is intended to help physicians treat arrhythmias through catheter-based procedures, with potential applications that include persistent atrial fibrillation and other complex rhythm disorders. Product availability and regulatory authorization may vary by geography and indication. Adagio Medical was founded in 2011 and is based in Laguna Hills, California. The company has focused primarily on research, clinical development and regulatory advancement of its ablation platform, serving the global electrophysiology and cardiovascular-care markets. Its leadership has included founder and Chief Executive Officer Olav Bergheim.View Adagio Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lamb Weston’s Turnaround Is Starting to Look RealAI Chip Demand Gives Linde a New Growth CatalystInvenTrust’s Sell-Off Opens a Potential Entry PointCuraleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02 Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
